Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.
Flávia Miranda,Hugo Prazeres,Fernando Mendes,Diana Martins,Fernando Schmitt,Fernando Schmitt +5 more
TLDR
In this article, the most promising predictive biomarkers of resistance in estrogen receptor-positive breast cancer and the emerging role of circulating free-DNA as a powerful tool for longitudinal monitoring of tumour molecular profile throughout treatment.Abstract:
Breast cancer is the most common cancer in women. It is a heterogeneous disease, encompassing different biological subtypes that differ in histological features, outcomes, clinical behaviour and different molecular subtypes. Therapy has progressed substantially over the past years with a reduction both for locoregional and systemic therapy. Endocrine therapies have considerably reduced cancer recurrence and mortality. Despite the major diagnostic and therapeutic innovations, resistance to therapy has become a main challenge, especially in metastatic breast cancer, and became a major factor limiting the use of endocrine therapeutic agents in ER positive breast cancers. Approximately 50% of patients with ER positive metastatic disease achieve a complete or partial response with endocrine therapy. However, in the remaining patients, the benefit is limited due to resistance, intrinsic or acquired, resulting in disease progression and poor outcome.Tumour heterogeneity as well as acquired genetic changes and therapeutics pressure have been involved in the endocrine therapy resistance. Nowadays, targeted sequencing of genes involved in cancer has provided insights about genomic tumour evolution throughout treatment and resistance driver mutations. Several studies have described multiple alterations in receptor tyrosine kinases, signalling pathways such as Phosphoinositide-3-kinase-protein kinase B/Akt/mTOR (PI3K/Akt/mTOR) and Mitogen-activated protein kinase (MAPK), cell cycle machinery and their implications in endocrine treatment failure.One of the current concern in cancer is personalized therapy. The focus has been the discovery of new potentially predictive biomarkers capable to identify reliably the most appropriate therapy regimen and which patients will experience disease relapse. The major concern is also to avoid overtreatment/undertreatment and development of resistance.This review focuses on the most promising predictive biomarkers of resistance in estrogen receptor-positive breast cancer and the emerging role of circulating free-DNA as a powerful tool for longitudinal monitoring of tumour molecular profile throughout treatment.read more
Citations
More filters
Journal ArticleDOI
Targeting HER2-positive breast cancer: advances and future directions
TL;DR: The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2targeted drug -the monoclonal antibody trastuzumab -almost 25 years ago as discussed by the authors .
Journal ArticleDOI
Culture of patient-derived multicellular clusters in suspended hydrogel capsules for pre-clinical personalized drug screening
Haijiang Dong,Ze-xi Li,Suchen Bian,Guangyuan Song,Wenfeng Song,Mingqi Zhang,Haiyang Xie,Shusen Zheng,Xuxu Yang,Tiefeng Li,Penghong Song +10 more
TL;DR: In this article , a simulation of the liver TME with suspended alginate-gelatin hydrogel capsules encapsulating patient-derived liver tumor multicellular clusters, and the culture of patient derived tumor organoids(PDTOs) for personalized pre-clinical drug screening is presented.
Journal ArticleDOI
Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions
TL;DR: This review summarizes detection technologies and novel agents for HER2-low BC, and explores their possible role in future clinics, to provide ideas for the diagnosis and treatment of Her2- low BC.
Journal ArticleDOI
Uncovering Evidence: Associations between Environmental Contaminants and Disparities in Women’s Health
Jelonia T Rumph,Victoria R. Stephens,Joanie L. Martin,Lakendria K. Brown,Portia L. Thomas,Ayorinde Cooley,Kevin G. Osteen,Kaylon L. Bruner-Tran +7 more
TL;DR: Evidence within the literature suggests that the body burden of environmental contaminants, especially in combination with inherent genetic variations, likely contributes to previously observed racial disparities in women’s health conditions such as breast cancer, endometriosis, polycystic ovarian syndrome, uterine fibroids, and premature birth.
Journal ArticleDOI
The cross-talk of autophagy and apoptosis in breast carcinoma: implications for novel therapies?
TL;DR: In this paper , the authors discuss the cross-talk of autophagy and apoptosis and the diverse facets of autoophagy in breast cancer cells leading to novel models for more effective therapeutic strategies.
References
More filters
Journal ArticleDOI
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more
TL;DR: Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.
Journal ArticleDOI
Proteogenomics connects somatic mutations to signalling in breast cancer
Philipp Mertins,D. R. Mani,Kelly V. Ruggles,Michael A. Gillette,Michael A. Gillette,Karl R. Clauser,Pei Wang,Xianlong Wang,Jana W. Qiao,Song Cao,Francesca Petralia,Emily Kawaler,Filip Mundt,Filip Mundt,Karsten Krug,Zhidong Tu,Jonathan T. Lei,Michael L. Gatza,Matthew D. Wilkerson,Charles M. Perou,Venkata Yellapantula,Kuan-lin Huang,Chenwei Lin,Michael D. McLellan,Ping Yan,Sherri R. Davies,R. Reid Townsend,Steven J. Skates,Jing Wang,Bing Zhang,Christopher R. Kinsinger,Mehdi Mesri,Henry Rodriguez,Li Ding,Amanda G. Paulovich,David Fenyö,Matthew J. Ellis,Steven A. Carr +37 more
TL;DR: It is demonstrated that proteogenomic analysis of breast cancer elucidates functional consequences of somatic mutations, narrows candidate nominations for driver genes within large deletions and amplified regions, and identifies therapeutic targets.
Journal ArticleDOI
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli,Nicholas C. Turner,Igor Bondarenko,Jungsil Ro,Seock-Ah Im,Norikazu Masuda,Marco Colleoni,Angela DeMichele,Sherene Loi,Sunil Verma,Hiroji Iwata,Nadia Harbeck,Ke Zhang,Kathy Puyana Theall,Yuqiu Jiang,Cynthia Huang Bartlett,Maria Koehler,Dennis J. Slamon +17 more
TL;DR: This study aimed to confirm the earlier findings with this extended follow-up and show the results for subgroup and biomarker analyses, and assesses endocrine therapy resistance by clinical parameters, quantitative hormone-receptor expression, and tumour PIK3CA mutational status in circulating DNA at baseline.
Journal ArticleDOI
Correction: Author Correction: Integrated genomic analyses of de novo pathways underlying atypical meningiomas
Akdes Serin Harmanci,Mark W. Youngblood,Victoria E. Clark,Süleyman Coşkun,Octavian Henegariu,Daniel Duran,E. Zeynep Erson-Omay,Leon D. Kaulen,Tong Ihn Lee,Brian J. Abraham,Matthias Simon,Boris Krischek,Marco Timmer,Roland Goldbrunner,S. Bulent Omay,Jacob F Baranoski,Burçin Baran,Geneive Carrión-Grant,Hanwen Bai,Ketu Mishra-Gorur,Johannes Schramm,Jennifer Moliterno,Alexander O. Vortmeyer,Kaya Bilguvar,Katsuhito Yasuno,Richard A. Young,Murat Gunel +26 more
TL;DR: This corrects the article DOI: 10.1038/ncomms14433 to indicate that the author of the paper is a doctor of medicine rather than a scientist, as previously reported.
Journal ArticleDOI
Treating cancer with selective CDK4/6 inhibitors
TL;DR: Results of pivotal phase III trials investigating palbociclib in patients with advanced-stage oestrogen receptor (ER)-positive breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile.